Clinical Trials

30 enrolled

Pancreatic Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Small Cell Lung Carcinoma

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT07279532 2025-12-12

Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

Phase 2 Active not recruiting

35 enrolled

Tumor-Agnostic

Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

32 enrolled

Pancreatic Neoplasms

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Phase 2 Terminated

78 enrolled 20 charts

EndocrineNET

Neuroendocrine Tumors

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2 Completed

22 enrolled

Pancreatic Neoplasms

NCT05165407 2025-03-14

NESSIE

Phase 2 Active not recruiting

30 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT06437353 2024-11-27

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Phase 2 Active not recruiting

74 enrolled

Gynecologic

Ovarian Neoplasms

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

28 enrolled

Cholangiocarcinoma

NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

60 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

80 enrolled

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

29 enrolled

NSCLC

NCT06375642 2024-04-19

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

30 enrolled

Cholangiocarcinoma

NCT05926492 2024-04-17

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

160 enrolled

Sarcoma

Osteosarcoma

NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

100 enrolled

Adenoma, Islet Cell

NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

41 enrolled

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05988372 2023-11-01

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

50 enrolled

Locally Advanced Pancreatic Cancer

NCT05989425 2023-08-14

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

32 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

61 enrolled

Colorectal Neoplasms

NCT05106777 2023-04-12

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

47 enrolled

Sarcoma

NCT05595889 2022-11-29

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

40 enrolled

Small Cell Lung Carcinoma

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

EndocrineGastrointestinal

60 enrolled

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT05003037 2022-11-04

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

106 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05186545 2022-09-02

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

63 enrolled

Breast

Breast Neoplasms

NCT05171439 2022-04-14

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

6 enrolled

Carcinoma, Hepatocellular

NCT05282433 2022-03-16

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

45 enrolled

Carcinoma, Hepatocellular

NCT04764006 2021-11-04

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

10 enrolled

Advanced Colorectal Cancer

NCT05030246 2021-09-01

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

72 enrolled

Refractory Metastatic Digestive System Carcinoma

NCT04910854 2021-06-02

Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

27 enrolled

Head & Neck

Head and Neck Cancers - Salivary Gland

NCT04524884 2020-08-24

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

10 enrolled

Head & Neck

Thyroid Neoplasms

NCT02614495 2020-02-13

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Phase 2 Completed

66 enrolled

Head & Neck

Thyroid Neoplasms

NCT02966821 2019-02-27

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase 2 Completed

39 enrolled